

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/856,319		Hidetoshi Uemura	UEMURA 5	6685
1444	7590 11/04/2003		EXAMINER	
BROWDY AND NEIMARK, P.L.L.C.			SULLIVAN, DANIEL M	
624 NINTH STREET, NW SUITE 300			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20001-5303			1636	-
			DATE MAILED: 11/04/2007	1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/856,319	UEMURA ET AL
Advisory Action	Examiner	Art Unit
	Daniel M Sullivan	1636
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence address
THE REPLY FILED 23 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ation. A proper reply to a
PERIOD FOR RE	PLY [check either a) or b)]	
 a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). 	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejection.
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the context (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	f extension and the corresponding amo he shortened statutory period for reply the later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF		
$2. \boxtimes$ The proposed amendment(s) will not be entered be	ecause:	
(a) 🛛 they raise new issues that would require furthe	er consideration and/or search (s	see NOTE below);
(b) they raise the issue of new matter (see Note b	elow);	
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the
(d) they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following rejection	on(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See		dered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly
7. For purposes of Appeal, the proposed amendment(explanation of how the new or amended claims wo		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>20-26,32,33,38,39,42 and 43</u> .		
Claim(s) withdrawn from consideration: 11-19,27-31	1,35-37,40 and 41.	
8. The proposed drawing correction filed on is a		roved by the Examiner.
9. Note the attached Information Disclosure Statemen		
10. Other:	2	PRIMARY EXAMINER

Continuation of 2. NOTE: According to the proposed amendment, claims 23 and 32 would be limited to determining the presence or amount of a protein consisting of the amino acid sequence of residues 1-231 of SEQ ID NO: 2 or 4. As even an antibody raised against a protein consisting of residues 1-231 of SEQ ID NO: 2 or 4 would not be able to distinguish proteins consisting of that sequence from proteins comprising that sequence, it is unclear how the method steps set forth would determine the presence or amount of a protein consisting of only residues 1-231 of SEQ ID NO: 2 or 4.

Continuation of 5. does NOT place the application in condition for allowance because: Applicant's arguments are predicated on the amendments to the claims filed therewith. As the amendments have not been entered, the arguments are moot. It is noted, however, that the proposed amendments would not overcome rejection of 20, 21, 23, 24, 25, 26, 33, 38 and 39 under 35 U.S.C. 102(b) as anticipated by Reseland et al. and claim 22 under 35 U.S.C. 103(a) as being unpatentable over Reseland et al. in view of Antibodies. Reseland et al. teaches antibodies raised against peptides that are comprised within residues 1-231 of SEQ ID NO: 2 or 4. Therefore, the antibody or Reseland et al. would react with a protein consisting of residues 1-231 of SEQ ID NO: 2 or 4. Furthermore, the proposed amendment to claim 42 does not fully address the grounds of rejection under 35 U.S.C. 112, first paragraph (enablement)..